Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Parmeshwar N Amatya, PhD, Alun J Carter, PhD BSc, Julie K Ritchey, Jessica Niswonger, Matthew L Cooper, PhD, Jonathan A Pachter, PhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139904

Published: 2020

Journal Articles

Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity

Parmeshwar Amatya, PhD, Matthew L. Cooper, PhD, Alun J Carter, PhD BSc, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2068.

https://doi.org/10.1182/blood-2019-126165

Published: 2019

Journal Articles

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Stephen P. Persaud, MD PhD, Matthew L. Cooper, PhD, Julie K. Ritchey, Michael P. Rettig, PhD, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 3200.

https://doi.org/10.1182/blood-2019-123519

Published: 2019

Journal Articles

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Melissa M Berrien-Elliott, PhD, Wong Pamela, B.S., Carly Neal, B.S., Julia A Wagner, PhD, Michelle Becker-Hapak, BS, Tim Schappe, BS, Matthew L. Cooper, PhD, Emily M Mace, PhD, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 3237.

https://doi.org/10.1182/blood-2019-129162

Published: 2019

Journal Articles

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Karl W. Staser, MD PhD, Matthew L. Cooper, PhD, Jaebok Choi, PhD, Anand Chukka, Kidist Ashami, BA, Jessica Niswonger, Jaehan Park, Byung Ha Lee, PhD, Shunqiang Li, PhD, Amanda F Cashen, MD, Amy Musiek, MD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 340.

https://doi.org/10.1182/blood-2018-99-119375

Published: 2018

Journal Articles

Baricitinib Prevents and Treats GvHD through Both Immune Modulation and Enhancement of Tissue Repair

Kidist Ashami, BA, Kiran R. Vij, MD, Julie Ritchey, Srikanth Santhanam, PhD, Karl W. Staser, MD PhD, Sora Lim, Sena Kim, Matthew L. Cooper, PhD, Feng Gao, PhD, Matthew Ciorba, John F. DiPersio, MD PhD, Jaebok Choi, PhD

Blood (2018) 132 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2018-99-119470

Published: 2018

Journal Articles

Conditioning for Hematopoietic Stem Cell Transplantation Using Antibody-Drug Conjugate Targeting CD45 Permits Engraftment across Immunologic Barriers

Steve P. Persaud, MD PhD, Matthew L. Cooper, PhD, Michael P. Rettig, PhD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2035.

https://doi.org/10.1182/blood-2018-99-116894

Published: 2018

Journal Articles

Selective Inhibition of α4β1 Integrin (VLA-4) Mitigates GvHD

Bader Alahmari, MD, Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Julie Ritchey, Bing Wang, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3344.

https://doi.org/10.1182/blood.V128.22.3344.3344

Published: 2016

Journal Articles

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Bing Wang, Julie Ritchey, Bader Alahmari, MD, Matthew Holt, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3353.

https://doi.org/10.1182/blood.V128.22.3353.3353

Published: 2016

Journal Articles

Targeting Alpha 4 Integrin (CD49d) to Reduce GvHD

Bader Alahmari, MBBS, Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Julie Ritchey, John F. DiPersio, MD PhD

Blood (2015) 126 (23): 4283.

https://doi.org/10.1182/blood.V126.23.4283.4283

Published: 2015

Journal Articles

A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results

Mark A. Schroeder, MD, Jaebok Choi, PhD, Matthew L Cooper, PhD, David Schwab, BA CCRP, Sarah Willey, Jingxia (Esther) Liu, PhD, Matthew Holt, Linda Eissenberg, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD, John S. Welch, MD PhD, Keith Stockerl-Goldstein, MD, Camille N. Abboud, MD FACP, Ravi Vij, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, John F Dipersio, MD PhD

Blood (2015) 126 (23): 1935.

https://doi.org/10.1182/blood.V126.23.1935.1935

Published: 2015

Journal Articles

Dysregulated Overexpression of S100A8 and S100A9 Calgranulin Family Proteins in IFNγR-/- Allogeneic T Cells Is Associated with Reduced Graft Versus Host Disease in Vivo

Matthew L Cooper, PhD, Jaebok Choi, PhD, Julie Ritchey, John F. DiPersio, MD PhD

Blood (2014) 124 (21): 3828.

https://doi.org/10.1182/blood.V124.21.3828.3828

Published: 2014

Journal Articles

Targeting VLA-4 to Reduce GvHD

Jaebok Choi, PhD, Matthew L Cooper, PhD, Bader Alahmari, MD, Julie Ritchey, John F. DiPersio, MD PhD

Blood (2014) 124 (21): 3829.

https://doi.org/10.1182/blood.V124.21.3829.3829

Published: 2014

Journal Articles

IFNγR Signaling As a Therapeutic Target To Prevent GvHD While Preserving Gvl

Jaebok Choi, PhD, Matthew L Cooper, PhD, Julie Ritchey, Lynne Collins, Julie Prior, David Piwnica-Worms, MD, PhD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 4464.

https://doi.org/10.1182/blood.V122.21.4464.4464

Published: 2013

Journal Articles

Defining The Mechanism Involved In The Inhibition Of GvHD By Azacytidine In Vivo Through The Use Of FoxP3 Diphtheria Toxin Receptor ( Foxp3 DTR ) Donor T Cells

Matthew L Cooper, PhD, Jaebok Choi, PhD, Julie Ritchey, John F. DiPersio, MD, PhD

Blood (2013) 122 (21): 134.

https://doi.org/10.1182/blood.V122.21.134.134

Published: 2013

Journal Articles

Use of FoxP3 Diptheria Toxin Receptor ( Foxp3 DTR ) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo

Matthew L Cooper, PhD, Jaebok Choi, PhD., Julie Ritchey, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 4113.

https://doi.org/10.1182/blood.V120.21.4113.4113

Published: 2012

NARROW

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Baricitinib Prevents and Treats GvHD through Both Immune Modulation and Enhancement of Tissue Repair

Conditioning for Hematopoietic Stem Cell Transplantation Using Antibody-Drug Conjugate Targeting CD45 Permits Engraftment across Immunologic Barriers

Selective Inhibition of α4β1 Integrin (VLA-4) Mitigates GvHD

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Targeting Alpha 4 Integrin (CD49d) to Reduce GvHD

A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results

Dysregulated Overexpression of S100A8 and S100A9 Calgranulin Family Proteins in IFNγR-/- Allogeneic T Cells Is Associated with Reduced Graft Versus Host Disease in Vivo

Targeting VLA-4 to Reduce GvHD

IFNγR Signaling As a Therapeutic Target To Prevent GvHD While Preserving Gvl

Defining The Mechanism Involved In The Inhibition Of GvHD By Azacytidine In Vivo Through The Use Of FoxP3 Diphtheria Toxin Receptor ( Foxp3 DTR ) Donor T Cells

Use of FoxP3 Diptheria Toxin Receptor ( Foxp3 DTR ) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only